BioStem Technologies reports developments tied to its regenerative medicine business, which develops, manufactures and commercializes perinatal tissue allograft products used by clinicians across wound care and other specialties. Company updates commonly cover financial results, conference calls, clinical research presentations, and product portfolio activity involving brands such as Neox, Clarix, VENDAJE and American Amnion.
BioStem news also includes governance and compliance appointments, board changes, audited financial statement publication, and integration of completed asset acquisitions that expand its surgical and wound-care product offerings. Its disclosures describe proprietary BioRetain, CryoTek and SteriTek processing technologies, AATB-accredited quality systems, and operations aligned with current Good Tissue Practices and current Good Manufacturing Processes.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived wound care products, has responded to CMS's proposed changes for skin substitute reimbursement in CY 2026. The company supports the reform efforts aimed at addressing Medicare spending in this category.
CEO Jason Matuszewski emphasized their commitment to working with stakeholders during the 60-day comment period to optimize reimbursement methodology. The company is conducting randomized controlled trials (RCTs) for their BioREtain® technology across multiple indications, with initial results expected later this year.
Additionally, BioStem is progressing with its Form 10 filing and plans to provide updates on its Nasdaq uplisting during Q2 2025 earnings call.
BioStem Technologies (OTC: BSEM), a leading MedTech company specializing in placental-derived products for advanced wound care, announces that Chairman and CEO Jason Matuszewski will present at the Advanced Wound Care Summit's Investor Forum on July 15, 2025, at 2:00 PM ET in Boston.
The presentation, titled "Invest in the Future of Advanced Wound Care with BioStem Technologies," will showcase the company's core allograft business and growth opportunities. BioStem leverages its proprietary BioREtain® processing method and maintains AATB accreditation and FDA registration for its Pompano Beach facility. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion and American Amnion AC.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announces its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami. CEO Jason Matuszewski will engage in a fireside chat and one-on-one meetings.
BioStem Technologies leverages its proprietary BioREtain® processing method to develop and manufacture allografts. The company's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® products. Their facility in Pompano Beach, Florida, is FDA registered and AATB accredited, operating under cGTP and cGMP standards.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has scheduled its first quarter 2025 financial results announcement for May 12, 2025.
The company will host a conference call and webcast at 4:30 PM ET, featuring presentations from CEO Jason Matuszewski and CFO Michael Fortunato. Investors can participate through:
- North America Toll-Free: (800) 715-9871
- International Toll: +1 (646) 307-1963
- Conference ID: 9695874
Interested parties can register for the webcast through the provided link and stay updated by joining BioStem's distribution list and following their social media channels on X and LinkedIn.